Navigation Links
Resverlogix Phase 1b/2a Study Meets Primary Endpoint
Date:8/25/2009

t (RCT).

RCT is a pathway by which accumulated cholesterol is transported from the arterial wall to the liver for excretion, thus preventing atherosclerosis. Major constituents of RCT include acceptors such as high-density lipoprotein (HDL) and apolipoprotein A-I (ApoA-I). A critical part of reverse cholesterol transport is cholesterol efflux, in which accumulated cholesterol is removed from macrophages.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas(TM) PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.


'/>"/>
SOURCE Resverlogix Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Resverlogixs Success in Inflammation Program Results in 2 Patents Filed
2. Resverlogix Provides Quarterly Update
3. Resverlogix Board of Directors Update
4. Resverlogix Advances to Second Arm of Phase 1b/2a Clinical Trial
5. Resverlogix Announces Closing of Debt Redemption
6. Resverlogix Eliminates Sixty Percent of Remaining Debt
7. Resverlogix Issues a Management Statement
8. Resverlogix Board of Directors Update
9. Resverlogix Notice of Conference Call & Webcast
10. Jan Gray Joins Resverlogix Board of Directors
11. Resverlogixs Lead Drug Featured in Key Scientific Publication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the ... develops and commercializes proprietary technologies and products for advanced ... for the second fiscal quarter ended March 31, 2015. ... to advance business with our existing customers and to ... and CEO of SQI. "The delivery of a fully ...
(Date:5/21/2015)... CA (PRWEB) May 21, 2015 ... has announced a partnership with PicnicHealth, a healthcare ... patients. Participants diagnosed with Inflammatory Bowel Disease (IBD) ... as a complementary uBiome research kit. Both companies ... , For more information on ...
(Date:5/21/2015)... 21, 2015  CytRx Corporation (NASDAQ: CYTR ... in oncology, today announced positive updated results from ... for the treatment of unresectable glioblastoma multiforme (GBM), ... multisite trial is designed to investigate the preliminary ... tumors have progressed following prior treatment with surgery, ...
(Date:5/21/2015)... of Prussia, PA (PRWEB) May 21, 2015 ... Julia O’Neill has joined the firm as senior statistician ... than 30 years of experience in the management and ... vaccines, biologics, pharmaceutical and chemical industries. , “We’re delighted ... our longstanding capabilities in data analytics,” said Dr. Philippe ...
Breaking Biology Technology:SQI Diagnostics Reports Second Quarter Financial Results 2SQI Diagnostics Reports Second Quarter Financial Results 3SQI Diagnostics Reports Second Quarter Financial Results 4SQI Diagnostics Reports Second Quarter Financial Results 5SQI Diagnostics Reports Second Quarter Financial Results 6SQI Diagnostics Reports Second Quarter Financial Results 7SQI Diagnostics Reports Second Quarter Financial Results 8uBiome Partners with PicnicHealth 2uBiome Partners with PicnicHealth 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2
... VIEW, Calif., Nov. 6 Frost & ... Innovation of the Year Award in,molecular/cellular imaging ... its,pioneering molecular platform for the targeting and ... platform, known as Aposense(R), is,an innovative set ...
... Calif., Nov. 6 ( http://www.amdl.com ),AMDL, Inc. ... with major operations in China and the U.S., ... Douglas MacLellan will present at,Rodman & Renshaw,s Annual ... 2008 at the New York Palace Hotel in ...
... Recognized As Safe) designation for Sucralose, Enhancer S2383, which allows commercialization ... for commercialization of S2383, - Initiation of safety studies to support ... ... with Solae to develop bitter blockers ...
Cached Biology Technology:Aposense Receives Frost & Sullivan Technology Innovation of the Year Award 2Aposense Receives Frost & Sullivan Technology Innovation of the Year Award 3Aposense Receives Frost & Sullivan Technology Innovation of the Year Award 4AMDL, Inc. New President & CEO Douglas MacLellan to Present at Rodman & Renshaw Annual Global Investment Conference November 12, 2008 2SENOMYX ANNOUNCES THIRD QUARTER 2008 FINANCIAL RESULTS 2SENOMYX ANNOUNCES THIRD QUARTER 2008 FINANCIAL RESULTS 3SENOMYX ANNOUNCES THIRD QUARTER 2008 FINANCIAL RESULTS 4SENOMYX ANNOUNCES THIRD QUARTER 2008 FINANCIAL RESULTS 5SENOMYX ANNOUNCES THIRD QUARTER 2008 FINANCIAL RESULTS 6SENOMYX ANNOUNCES THIRD QUARTER 2008 FINANCIAL RESULTS 7SENOMYX ANNOUNCES THIRD QUARTER 2008 FINANCIAL RESULTS 8SENOMYX ANNOUNCES THIRD QUARTER 2008 FINANCIAL RESULTS 9SENOMYX ANNOUNCES THIRD QUARTER 2008 FINANCIAL RESULTS 10SENOMYX ANNOUNCES THIRD QUARTER 2008 FINANCIAL RESULTS 11SENOMYX ANNOUNCES THIRD QUARTER 2008 FINANCIAL RESULTS 12SENOMYX ANNOUNCES THIRD QUARTER 2008 FINANCIAL RESULTS 13SENOMYX ANNOUNCES THIRD QUARTER 2008 FINANCIAL RESULTS 14
(Date:5/6/2015)... , May 6, 2015 LifeBEAM, a developer ... helmet producer, announced today that they will expand their ... world,s first bio-sensing cycling helmet and the first joint ... two new colors in order to give cyclists more ... In addition, LifeBEAM and Lazer announced their plan to ...
(Date:4/21/2015)... , April 21, 2015 ... government policies are boosting access control systems market in ... According to a recently published report by TechSci Research ... ", the access control systems market in ... billion by 2020.The access control systems market in the ...
(Date:4/14/2015)... , April 14, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, ... for the 2015 New York Design Awards under the ... New York City Design Awards are part of a ... over 2,500 ratings from the marketplace, industry and judging ...
Breaking Biology News(10 mins):LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... with sporadic amyotrophic lateral sclerosis demonstrated that a ... was significantly associated with sporadic amyotrophic lateral sclerosis ... Daojun Hong and colleagues from Nanchang University further ... sporadic amyotrophic lateral sclerosis in the Chinese Han ...
... synonymisation with Meloidogyne ulmi , a species known to ... M. mali has been in the Netherlands for ... suggest that M. mali was probably introduced during ... (DED) during which large numbers of Elm rootstocks and seeds ...
... , TORONTO, Dec. 30, 2013Fructose, the sugar often blamed ... impact on an emerging marker for the risk of ... found., However, overconsumption of calories from fructose can have ... a researcher in the Clinical Nutrition and Risk Factor ...
Cached Biology News:Meloidogyne mali: A new invasive plant parasitic nematode in Europe 2
... T4 Polynucleotide Kinase (PNK) catalyzes the ... to the 5'-hydroxyl of single- and ... The enzyme also removes the 3'-phosphate ... deoxyribonucleoside 3', 5'-diphosphates to form a ...
Request Info...
Maxi 14 Hybridization Oven. 14 bottle (35 mm) rotisserie + shaker tray available for simultaneous use. Includes linear and orbital shaker trays, 4 medium bottles, pack of mesh, bottle gripper and d...
Request Info...
Biology Products: